72% Pharma Sales Professionals have a fear of losing job due to COVID 19 pandemic..,

In a recently conducted online survey involving 2206 pharmaceutical sales professionals, it is found that 72% of them have a fear of losing job due to COVID 19 pandemic. In these days people assume that pharmaceutical and healthcare are the 2 industries which are growing due to pandemic and this survey observation is completely reverse.

K K Consulting Services, Mumbai recently conducted this survey involving pharmaceutical sales professionals from all over India. >50% participants of this survey have more than 10 years’ experience in pharmaceutical sales and around 59% of participants are presently working as team manager. Information received from such experienced professionals can’t be ignored.

Fear of losing job is observed slightly more among team managers than the medical representatives. Participants from East & North zone of India has observed with more fear of losing job (74%) than that of other 2 zones. West (71%), South (69%)

It is observed that participants feels that it will take around 0-6 month time to start doctors sales calls the normal way as it was happening before COVID pandemic.

To know more insight of this survey, connect K K Consulting Services, Mumbai at info@kkconsultingservices.com

Disclaimer

The opinions expressed in the survey do not reflect the opinions of KK Consulting Services or its Editors. Information contained in published results have been obtained from the survey. However, no author’s guarantees the accuracy or completeness of any information published herein and authors shall beresponsible for any errors, omissions, or claims for damages, arising out of use, inability to use, or with regard to the accuracy or sufficiency of the information contained in publications. No responsibility is assumed by the Publisher or Editors for any damage to persons or property as a matter of negligence, or otherwise, or from any use of informationby any methods, product, instructions, or ideas contained in the published material. Information in this publication is current as on date 6th July 2020.

All rights reserved. No part of any published work may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher.

Related Posts

Supreme Court declines plea to make nucleic acid tests compulsory at blood banks

New Delhi:  The Supreme Court on Friday (March 13, 2026) refused to direct the government to compulsorily conduct “expensive” Nucleic Acid Tests (NAT) to identify diseases ahead of blood transfusions,…

Jaipur: Fraudster Arun Kumar Arrested for Extorting Medical Store Owners by Posing as Drug Inspector

Jaipur— Brahmpuri police in Jaipur have arrested a notorious fraudster who systematically extorted money from medical store owners by impersonating a Drug Inspector. The same accused, Arun Kumar, also cheated…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Supreme Court declines plea to make nucleic acid tests compulsory at blood banks

Supreme Court declines plea to make nucleic acid tests compulsory at blood banks

Jaipur: Fraudster Arun Kumar Arrested for Extorting Medical Store Owners by Posing as Drug Inspector

Jaipur: Fraudster Arun Kumar Arrested for Extorting Medical Store Owners by Posing as Drug Inspector

India’s Medical Devices Sector Logs 4,108 Licensed Manufacturers and ₹20,658 Crore FDI Inflows Since 2018

India’s Medical Devices Sector Logs 4,108 Licensed Manufacturers and ₹20,658 Crore FDI Inflows Since 2018

Abbott introduces its most advanced drug eluting stent XIENCE Skypoint™ in India

Abbott introduces its most advanced drug eluting stent XIENCE Skypoint™ in India

Top 30 pharma companies post 12% revenue growth in first nine months

Top 30 pharma companies post 12% revenue growth in first nine months

India Cracks Down On Ads For Weight-Loss Drugs Like GLP-1 In New Advisory

India Cracks Down On Ads For Weight-Loss Drugs Like GLP-1 In New Advisory